Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542148 · ClinicalTrials.gov registry record · Phase 2
Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes
A Phase 2 study of Diabetes Mellitus, Type 2 and Preterm Birth, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT04542148 is a Phase 2 study of Diabetes Mellitus, Type 2 and Preterm Birth that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 120 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04542148, a Phase 2 study of Diabetes Mellitus, Type 2 and Preterm Birth, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
There is a fundamental gap in understanding the maternal and neonatal effects of antenatal corticosteroid (ACS) administration in women with threatened preterm birth (PTB) who have diabetes. Since the initial discovery of ACS for neonatal benefit in 1972, more than 40 randomized controlled trials have been performed evaluating its efficacy. However, none of these trials have included women with T2DM, and there is limited data among women with gestational diabetes. While ACS have been shown to reduce neonatal morbidity associated with PTB in non-diabetic women, the side effects of ACS (maternal hyperglycemia and fetal hyperinsulinemia) may mitigate the neonatal benefit of ACS in women with diabetes. Before neonatal benefit of ACS can be evaluated in this population, the first step is to optimize maternal glycemic control after ACS. Previous studies evaluating maternal hyperglycemia after ACS have been limited by small sample size, retrospective study design, or insufficient glucose data. Use of continuous glucose monitoring (CGM) in a randomized clinical trial provides a unique opportunity to overcome these challenges. Our long-term goal is to improve maternal and child health among women with diabetes as an independently funded clinical researcher. The research objectives of this proposal are to test the efficacy of three treatment strategies at achieving maternal glycemic control after ACS and evaluate the association between maternal glycemic control and neonatal outcomes. Our central hypothesis is that treatment with a continuous insulin infusion will improve maternal glycemic control, which is key to improving neonatal outcomes, but at the cost of less patient satisfaction and more health resource utilization. This hypothesis will be tested by pursuing the following specific aims: 1) Test the efficacy of three treatment strategies (addition of sliding scale insulin, up-titration of home insulin, and continuous insulin infusion) at achieving maternal glycemic con
Conditions Studied
Interventions
- DRUG Sliding Scale Insulin
- DRUG Up-Titration of Home Insulin
- DRUG Continuous Insulin Infusion
- DEVICE Dexcom G6 Professional Continuous Glucose Monitor
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
Oregon
- Oregon Health and Science University - Portland
South Carolina
- University of South Carolina Greenville / Prisma Health-Upstate - Greenville
Texas
- University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542148
The ClinicalTrials.gov registry entry for NCT04542148 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Sliding Scale Insulin is the first listed.
NCT04542148 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Oregon, South Carolina.
Frequently Asked Questions
What is clinical trial NCT04542148 about?
NCT04542148 is a clinical study titled "Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes". There is a fundamental gap in understanding the maternal and neonatal effects of antenatal corticosteroid (ACS) administration in women with threatened preterm birth (PTB) who have diabetes. Since the initial discovery of ACS for neonatal benefit in 1972, more than 40 randomized controlled trials ha...
What is the current status of trial NCT04542148?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-02-10. Estimated completion is 2026-05-31.
What conditions does trial NCT04542148 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational.
What interventions are being tested in trial NCT04542148?
The interventions under investigation include: Sliding Scale Insulin (DRUG), Up-Titration of Home Insulin (DRUG), Continuous Insulin Infusion (DRUG), Dexcom G6 Professional Continuous Glucose Monitor (DEVICE).
Who is sponsoring clinical trial NCT04542148?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04542148 being conducted?
This trial has 4 study locations across Alabama, Oregon, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.